Adjunct to diet for patients w/ elevated total cholesterol (total-C), LDL-C, Apo B & triglycerides & to increase HDL-C in patients w/ primary hypercholesterolemia (heterozygous familial & non-familial), combined (mixed) hyperlipidemia, elevated serum triglyceride levels & for patients w/ dysbetalipoproteinemia who do not respond adequately to diet. Reduction of total-C & LDL-C in patients w/ HoFH. Prevention of CV disease w/o clinically evident CHD but w/ multiple risk factors eg, age, smoking, HTN, low HDL-C or family history of early CHD for reduction of risk of MI, stroke, revascularisation procedures & angina. In type 2 diabetes w/o clinically evident CHD but w/ multiple risk factors eg, retinopathy, albuminuria, smoking or HTN for reduction of risk of MI & stroke. In patients w/ clinically evident CHD for reduction of risk of non-fatal MI, fatal & non-fatal stroke, angina, revascularisation procedures & hospitalisation for CHF. Adjunct to diet to reduce total-C, LDL-C & apo B levels in boys & postmenarchal girls 10-17 yr w/ heterozygous familial hypercholesterolemia if LDL-C ≤190 mg/dL or ≥160 mg/dL & there is +ve family history of premature CV disease or ≥2 other CV disease risk factors remains after adequate diet therapy.
Dosage/Direction for Use
Dose range: 10-80 mg once daily. Primary hypercholesterolemia & combined (mixed) hyperlipidemia 10 mg once daily. HoFH Most patient responded to 80 mg once daily. Heterozygous familial hypercholesterolemia in ped patient (10-17 yr) Initially 10 mg daily, dose adjustments made at ≥4 wk intervals. Max: 20 mg daily. Childn HoFH Up to 80 mg daily.
*The product images shown are for illustration purposes only and may not be an exact representation of the product.